TriangleNCT02793544 · OUTCOME
Cumulative Incidence of Chronic GVHD
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 90% Confidence Interval
- Time frame
- 180 days and 365 days post-transplant
What was measured
Per National Institutes of Health (NIH) Consensus Criteria and includes organ involvement and severity, and overall global composite score (mild/moderate/severe). A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.
Groups in this outcome
Myeloablative Conditioning (MAC)
Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan
Reduced Intensity Conditioning (RIC)
Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation
| Group | Source count |
|---|---|
| Myeloablative Conditioning (MAC) | 40 |
| Reduced Intensity Conditioning (RIC) | 40 |
Reported measurements
180 days
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Myeloablative Conditioning (MAC) | 27.6 | Not reported | 16.7 | 40.2 | Not reported |
| Reduced Intensity Conditioning (RIC) | 10 | Not reported | 3.6 | 19.2 | Not reported |
365 days
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Myeloablative Conditioning (MAC) | 35.5 | Not reported | 23.3 | 48.7 | Not reported |
| Reduced Intensity Conditioning (RIC) | 17.5 | Not reported | 8.7 | 28.5 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 16.7
- upper Limit
- 40.2
- value
- 27.6
- group Id
- OG001
- lower Limit
- 3.6
- upper Limit
- 19.2
- value
- 10
- title
- 180 days
- categories
- measurements
- group Id
- OG000
- lower Limit
- 23.3
- upper Limit
- 48.7
- value
- 35.5
- group Id
- OG001
- lower Limit
- 8.7
- upper Limit
- 28.5
- value
- 17.5
- title
- 365 days
- denoms
- counts
- group Id
- OG000
- value
- 40
- group Id
- OG001
- value
- 40
- units
- Participants
- description
- Per National Institutes of Health (NIH) Consensus Criteria and includes organ involvement and severity, and overall global composite score (mild/moderate/severe). A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.
- dispersion Type
- 90% Confidence Interval
- groups
- description
- Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan
- id
- OG000
- title
- Myeloablative Conditioning (MAC)
- description
- Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation
- id
- OG001
- title
- Reduced Intensity Conditioning (RIC)
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 180 days and 365 days post-transplant
- title
- Cumulative Incidence of Chronic GVHD
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice